Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study.
Hołowiecki J, Giebel S, Krzemień S, Krawczyk-Kuliś M, Jagoda K, Kopera M, Hołowiecka B, Grosicki S, Hellmann A, Dmoszyńska A, Paluszewska M, Robak T, Konopka L, Maj S, Wojnar J, Wojciechowska M, Skotnicki A, Baran W, Cioch M. Hołowiecki J, et al. Among authors: kopera m. Leuk Lymphoma. 2002 Feb;43(2):315-25. doi: 10.1080/10428190290006099. Leuk Lymphoma. 2002. PMID: 11999563 Clinical Trial.
Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G, Stella-Holowiecka B, Wojnar J, Krawczyk M, Krzemien S, Wojciechowska-Sadus M, Markiewicz M, Wylezol I, Kopera M, Holowiecki J. Helbig G, et al. Among authors: kopera m. Ann Hematol. 2007 Sep;86(9):677-83. doi: 10.1007/s00277-007-0304-8. Epub 2007 May 8. Ann Hematol. 2007. PMID: 17486341
Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, Holowiecki J, Holowiecka-Goral A, Markiewicz M, Kopera M, Karolczyk A, Kyrcz-Krzemien S, Kusnierczyk P. Giebel S, et al. Among authors: kopera m. Eur J Haematol. 2009 Oct;83(4):343-56. doi: 10.1111/j.1600-0609.2009.01280.x. Epub 2009 Jun 2. Eur J Haematol. 2009. PMID: 19500138
Autologous Hematopoietic Stem Cell Transplantation for High-risk Acute Lymphoblastic Leukemia: non-Randomized Study with a maximum Follow-up of more than 22 Years.
Helbig G, Krawczyk-Kulis M, Kopera M, Jagoda K, Rzepka P, Majewska-Tessar A, Hejla M, Kyrcz-Krzemien S. Helbig G, et al. Among authors: kopera m. Mediterr J Hematol Infect Dis. 2014 Jul 1;6(1):e2014047. doi: 10.4084/MJHID.2014.047. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 25045455 Free PMC article.
Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M, Kopera M, Kruzel T, Najda J, Nowak K, Holowiecki J. Helbig G, et al. Among authors: kopera m. Haematologica. 2005 Nov;90 Suppl:ECR33. Haematologica. 2005. PMID: 16266924
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Walewski J, Kraszewska E, Mioduszewska O, Romejko-Jarosińska J, Hellmann A, Czyz J, Hołowiecki J, Kopera M, Grosicki S, Komarnicki M, Rumianowski L, Kuliczkowski K, Wróbel T, Dwilewicz-Trojaczek J, Robak T, Warzocha K, Załuski J, Wójcik E, Dmoszyńska A, Walter-Croneck A; Polish Lymphoma Research Group. Walewski J, et al. Among authors: kopera m. Med Oncol. 2001;18(2):141-8. doi: 10.1385/mo:18:2:141. Med Oncol. 2001. PMID: 11778760 Clinical Trial.
[A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J, Konopka L, Bober G, Giebel S, Ceglarek B, Kos K, Stella-Hołowiecka B, Kruzel T, Kopera M, Bartkowska-Chrobok A, Pszenna E, Sikorska A, Pieńikowska-Grela B. Hołowiecki J, et al. Among authors: kopera m. Pol Arch Med Wewn. 2006 Jun;115(6):535-44. Pol Arch Med Wewn. 2006. PMID: 17263225 Clinical Trial. Polish.
83 results